Danaher (NYSE:DHR) PT Raised to $271.00

Danaher (NYSE:DHR) had its price target upped by Robert W. Baird from $259.00 to $271.00 in a research note issued to investors on Wednesday, Benzinga reports. The firm currently has an “outperform” rating on the conglomerate’s stock. Robert W. Baird’s price objective suggests a potential upside of 7.07% from the company’s current price.

A number of other brokerages have also recently issued reports on DHR. Barclays upped their price target on shares of Danaher from $240.00 to $260.00 and gave the stock an “equal weight” rating in a research note on Wednesday, April 10th. Royal Bank of Canada upped their target price on shares of Danaher from $254.00 to $282.00 and gave the stock an “outperform” rating in a research note on Wednesday, January 31st. Citigroup raised their price target on shares of Danaher from $255.00 to $280.00 and gave the company a “buy” rating in a research report on Wednesday, January 31st. StockNews.com cut Danaher from a “buy” rating to a “hold” rating in a research report on Wednesday, January 31st. Finally, KeyCorp lifted their target price on Danaher from $260.00 to $290.00 and gave the stock an “overweight” rating in a report on Thursday, February 1st. Six research analysts have rated the stock with a hold rating and eleven have given a buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $268.00.

Danaher Trading Up 7.2 %

DHR opened at $253.11 on Wednesday. The business has a 50 day moving average of $248.95 and a 200-day moving average of $230.64. The company has a quick ratio of 1.37, a current ratio of 1.68 and a debt-to-equity ratio of 0.31. The stock has a market cap of $187.44 billion, a PE ratio of 39.61, a PEG ratio of 3.96 and a beta of 0.83. Danaher has a 52 week low of $182.09 and a 52 week high of $259.00.

Danaher (NYSE:DHR) last released its earnings results on Tuesday, January 30th. The conglomerate reported $2.09 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.91 by $0.18. The firm had revenue of $6.41 billion during the quarter, compared to analyst estimates of $6.10 billion. Danaher had a net margin of 17.26% and a return on equity of 12.25%. The business’s revenue was down 10.2% on a year-over-year basis. During the same period last year, the business earned $2.87 earnings per share. Equities research analysts predict that Danaher will post 7.62 earnings per share for the current fiscal year.

Insider Transactions at Danaher

In other news, Director Teri List sold 3,289 shares of Danaher stock in a transaction on Tuesday, February 6th. The shares were sold at an average price of $248.32, for a total transaction of $816,724.48. Following the transaction, the director now owns 19,726 shares in the company, valued at approximately $4,898,360.32. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. In other news, SVP Georgeann Couchara sold 2,622 shares of the stock in a transaction on Tuesday, February 13th. The shares were sold at an average price of $242.67, for a total value of $636,280.74. Following the completion of the sale, the senior vice president now directly owns 4,244 shares of the company’s stock, valued at $1,029,891.48. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director Teri List sold 3,289 shares of Danaher stock in a transaction on Tuesday, February 6th. The shares were sold at an average price of $248.32, for a total transaction of $816,724.48. Following the transaction, the director now owns 19,726 shares in the company, valued at approximately $4,898,360.32. The disclosure for this sale can be found here. Insiders have sold 32,957 shares of company stock worth $8,265,802 in the last quarter. Company insiders own 10.90% of the company’s stock.

Institutional Trading of Danaher

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. Norges Bank bought a new stake in shares of Danaher in the 4th quarter worth about $1,752,382,000. Wellington Management Group LLP lifted its stake in shares of Danaher by 18.6% in the 3rd quarter. Wellington Management Group LLP now owns 24,930,281 shares of the conglomerate’s stock valued at $6,185,203,000 after purchasing an additional 3,905,449 shares during the last quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main boosted its holdings in shares of Danaher by 214.4% in the 4th quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main now owns 3,073,661 shares of the conglomerate’s stock worth $711,051,000 after purchasing an additional 2,096,038 shares during the period. Price T Rowe Associates Inc. MD increased its position in shares of Danaher by 10.7% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 16,757,558 shares of the conglomerate’s stock valued at $3,876,694,000 after purchasing an additional 1,619,586 shares during the last quarter. Finally, Capital International Investors raised its holdings in Danaher by 9.1% during the 4th quarter. Capital International Investors now owns 15,956,519 shares of the conglomerate’s stock valued at $3,691,735,000 after buying an additional 1,334,781 shares during the period. Institutional investors own 79.05% of the company’s stock.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.